Developing Therapeutics That Teach the Body to Heal Itself
Our team personally cares about the people we serve. We make progress every day to end suffering and premature death from serious human diseases. The Newsletter is one quick way keep track of AGT's advancements on all its programs and other events happening at the company. We look forward to keeping you up to date on our mission.
Exciting HIV Clinical Trial Update American Gene Technologies’ HIV Cure Clinical Trial Enters Critical Phase: Withdrawing Participants from Antiretrovirals. “This is a critical step in our mission to cure HIV using gene therapy,” said Am...
HIV Program Treatment Withdrawal Safety and efficacy blood markers have been recorded in the Phase 1 human trial for AGT’s HIV cure. We expect the antiretroviral treatment withdrawal studies to start this quarter. Six patients have recei...
HIV Program Update Five for Five! American Gene Technologies (AGT) announced that it has reached another important milestone in its HIV cure program. Five participants were treated with AGT103-T and are stably engrafted with genetically ...
HIV Program Update Enrolled First Cohort Since our last Newsletter, AGT has enrolled its first cohort of six participants in its Phase 1 study of AGT103-T against HIV. Updates on the RePAIR Clinical Trial (AGT103-T) Clinical Update [RePA...
We’ve achieved a number of significant milestones this quarter, including the Food and Drug Administration (FDA) clearance to begin Phase 1 of our HIV cure program. The excitement hasn’t only been within our walls; AGT has appeared in p...
FDA Progress The Path to the Clinic For the HIV Cure This month, AGT saw tremendous progress with the FDA. FDA time and attention to our project has seemed to increase while agency review responses to our submissions have narrowed to u...
Subscribe to our newsletter to keep up to date with all the latest news about AGT!
